- Home
- UWMC vs CRMD Comparison
UWMC vs CRMD Comparison
Compare UWMC & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- CRMD
- Stock Information
- Founded
- UWMC 1986
- CRMD 2006
- Country
- UWMC United States
- CRMD United States
- Employees
- UWMC N/A
- CRMD N/A
- Industry
- UWMC Finance: Consumer Services
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- CRMD Health Care
- Exchange
- UWMC Nasdaq
- CRMD Nasdaq
- Market Cap
- UWMC 876.2M
- CRMD 901.8M
- IPO Year
- UWMC N/A
- CRMD 2010
- Fundamental
- Price
- UWMC $5.82
- CRMD $13.69
- Analyst Decision
- UWMC Hold
- CRMD Strong Buy
- Analyst Count
- UWMC 7
- CRMD 7
- Target Price
- UWMC $5.54
- CRMD $16.83
- AVG Volume (30 Days)
- UWMC 10.2M
- CRMD 3.4M
- Earning Date
- UWMC 08-07-2025
- CRMD 08-07-2025
- Dividend Yield
- UWMC 6.87%
- CRMD N/A
- EPS Growth
- UWMC 112.84
- CRMD N/A
- EPS
- UWMC 0.07
- CRMD 0.79
- Revenue
- UWMC $2,622,828,000.00
- CRMD $121,484,498.00
- Revenue This Year
- UWMC $16.65
- CRMD $278.96
- Revenue Next Year
- UWMC $16.18
- CRMD $45.85
- P/E Ratio
- UWMC $87.80
- CRMD $17.30
- Revenue Growth
- UWMC 13.45
- CRMD 14970.29
- 52 Week Low
- UWMC $3.80
- CRMD $4.87
- 52 Week High
- UWMC $9.74
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- UWMC 72.08
- CRMD 65.34
- Support Level
- UWMC $5.27
- CRMD $12.80
- Resistance Level
- UWMC $5.68
- CRMD $13.56
- Average True Range (ATR)
- UWMC 0.30
- CRMD 0.86
- MACD
- UWMC 0.09
- CRMD 0.27
- Stochastic Oscillator
- UWMC 95.56
- CRMD 84.47
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.